WELWYN GARDEN CITY, UK and BOSTON, September 28, 2012 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery company, announces that its Chief Executive Officer, Malcolm Weir, will represent the Company at the 12th Annual Biotech in Europe Investor Forum, which takes place at the Hilton Zurich Airport Hotel, Zurich, Switzerland (1-2 October 2012).
On 1 October at 11:15am (CET), Dr Weir will participate in a panel discussion entitled "Platform Technologies and Novel Therapeutics."
In addition, at 3:45pm (CET) the same day, Dr Weir will present an overview of Heptares and will describe the significant progress the Company has made towards the discovery and development of breakthrough medicines targeting previously undruggable GPCRs.
About Heptares Therapeutics
Heptares discovers and develops new medicines targeting GPCRs (G protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune and Takeda, and we have raised $40M from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures.
Heptares is pioneering the application of structure-based drug design to the GPCR superfamily of targets and is focused on creating molecules that modulate high-value, yet historically undruggable or challenging, GPCRs. Our platform incorporates proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time.
Using this approach, we have generated a broad pipeline of drug candidates for the treatment of serious disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression, chronic insomnia, addiction disorders, and diabetes. For more information about Heptares, please visit http://www.heptares.com.
SOURCE Heptares Therapeutics